Skip to main content
  • TWILIGHT-ACS: Ticagrelor Alone after 3 Months of DAPT in NSTE-ACS Patients Reduces Bleeding without Increasing Ischemic Events vs. 12 months of DAPT

    Ticagrelor monotherapy after 3 months of dual antiplatelet therapy (DAPT) in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) effectively reduces major and clinically significant bleeding in comparison with 12 months of traditional DAPT (ticagrelor plus aspirin) and does not increase ischemic events, according to results presented Sunday at the American Heart Association Scientific Sessions 2019 in Philadelphia.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details